Last reviewed · How we verify

MT-7117 high dose

Tanabe Pharma America, Inc. · Phase 3 active Small molecule

MT-7117 high dose is a Soluble guanylate cyclase (sGC) activator Small molecule drug developed by Tanabe Pharma America, Inc.. It is currently in Phase 3 development for Pulmonary arterial hypertension (PAH). Also known as: Dersimelagon.

MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.

MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH).

At a glance

Generic nameMT-7117 high dose
Also known asDersimelagon
SponsorTanabe Pharma America, Inc.
Drug classSoluble guanylate cyclase (sGC) activator
TargetSoluble guanylate cyclase (sGC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

MT-7117 directly activates soluble guanylate cyclase, an enzyme that produces cyclic guanosine monophosphate (cGMP), a key signaling molecule in vascular smooth muscle relaxation. By increasing cGMP levels, the drug promotes vasodilation and reduces pulmonary vascular resistance, making it potentially beneficial for pulmonary hypertension. This mechanism differs from phosphodiesterase-5 inhibitors, which prevent cGMP breakdown rather than stimulating its production.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MT-7117 high dose

What is MT-7117 high dose?

MT-7117 high dose is a Soluble guanylate cyclase (sGC) activator drug developed by Tanabe Pharma America, Inc., indicated for Pulmonary arterial hypertension (PAH).

How does MT-7117 high dose work?

MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.

What is MT-7117 high dose used for?

MT-7117 high dose is indicated for Pulmonary arterial hypertension (PAH).

Who makes MT-7117 high dose?

MT-7117 high dose is developed by Tanabe Pharma America, Inc. (see full Tanabe Pharma America, Inc. pipeline at /company/tanabe-pharma-america-inc).

Is MT-7117 high dose also known as anything else?

MT-7117 high dose is also known as Dersimelagon.

What drug class is MT-7117 high dose in?

MT-7117 high dose belongs to the Soluble guanylate cyclase (sGC) activator class. See all Soluble guanylate cyclase (sGC) activator drugs at /class/soluble-guanylate-cyclase-sgc-activator.

What development phase is MT-7117 high dose in?

MT-7117 high dose is in Phase 3.

What are the side effects of MT-7117 high dose?

Common side effects of MT-7117 high dose include Headache, Dizziness, Hypotension, Dyspepsia.

What does MT-7117 high dose target?

MT-7117 high dose targets Soluble guanylate cyclase (sGC) and is a Soluble guanylate cyclase (sGC) activator.

Related